[Bisphosphonates-associated osteonecrosis of the jaw: review on reported cases].
Osteonecrosis of the jaws associated with the use of bisphosphonates (alendronate, pamidronate, risedronate et zoledronate) are described as an avascular necrosis. We have listed 184 cases of bisphosphonates-associated osteonecrosis of the maxillary in the literature. Many mechanisms are discussed in bisphosphonates-associated osteonecrosis: a disturbing bone turnover, an accumulation of bone's microdamage or an antiangiogenic effect. Other risk factors seem however to be involved: cancer, chemotherapy, glucocorticoids, infection and renal insufficiency.
Gering
Audrey
A
Centre Hospitalo Universitaire de Grenoble, Centre de pharmacovigilance, Grenoble, France.
Grange
Laurent
L
Villier
Céline
C
Woeller
Anne
A
Mallaret
Michel
M
D000368:Aged; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D010020:Osteonecrosis / Q000139:chemically induced* / Q000453:epidemiology
D050071:Bone Density Conservation Agents; D004164:Diphosphonates